| ISSN |
2218-4333 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Case Report |
| Article Title |
Recurrent aggressive mesenteric desmoid tumor successfully treated with sorafenib: A case report and review of literature
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Aikaterini Mastoraki, Dimitrios Schizas, Chrysovalantis Vergadis, Leon Naar, Alexios Strimpakos, Michail G Vailas, Natasha Hasemaki, George Agrogiannis, Theodore Liakakos and Nikolaos Arkadopoulos |
| Funding Agency and Grant Number |
|
| Corresponding Author |
Aikaterini Mastoraki, MD, PhD, Academic Research, Doctor, Lecturer, Surgeon, 4th Department of Surgery, National and Kapodistrian University of Athens, Attikon University Hospital, 1, Rimini Street, Chaidari, Athens 11527, Greece. dr_kamast@yahoo.gr |
| Key Words |
Desmoid tumor; Aggressive fibromatosis; Case report; Pathogenesis; Therapeutic approach; Sorafenib treatment |
| Core Tip |
Desmoid tumors (DT) are locally advanced but histologically benign monoclonal neoplasms that can occur from any musculoaponeurotic structure. DT’s pathogenesis has been associated with mutations of adenomatous polyposis coli (APC) gene or beta-catenine gene CTNNB1, sex steroids or previous surgical trauma. Local treatment modalities, such as surgery or radiotherapy, are implemented in aggressively progressing or symptomatic patients. Sorafenib is a hopeful therapeutic option against DTs, while several pharmacological agents have successfully been tried including dacarbazine-doxorubicin, anti-oestrogens, non-steroidal anti-inflammatory drugs, imatinib mesylate and sunitinib. |
| Publish Date |
2019-04-24 15:39 |
| Citation |
Mastoraki A, Schizas D, Vergadis C, Naar L, Strimpakos A, Vailas MG, Hasemaki N, Agrogiannis G, Liakakos T, Arkadopoulos N. Recurrent aggressive mesenteric desmoid tumor successfully treated with sorafenib: A case report and review of literature. World J Clin Oncol 2019; 10(4): 183-191 |
| URL |
https://www.wjgnet.com/2218-4333/full/v10/i4/183.htm |
| DOI |
https://dx.doi.org/10.5306/wjco.v10.i4.183 |
